Saturday, March 22
Lawrence Business Magazine LLC
Lawrence Business Magazine LLC
2014 Fourth Quarter - New & Growing Technology

CritiTech & Deciphera

By on 92 Comments
INNOVATION: DEVELOPING NEW DRUGS AND NEW DRUG DELIVERY SYSTEMS IN LAWRENCE
| 2014 Q4 | story by LIZ WESLANDER    | photos by STEVEN HERTZOG |
Tech

Deciphera lab

Hidden in plain sight among unassuming buildings in downtown and north Lawrence are two high-tech biotechnology companies that are working on innovative cancer treatments that could be available on the market in the future.

CritiTech, a Lawrence born-and-bred drug development company, operates both its labs and business offices in a space along E. 1450 Rd just north of downtown. Deciphera, with its business headquarters in Boston, Mass. has biology and chemistry labs located on the 600 block of Massachusetts Street- right across from the Free State Brewery.

Daniel Flynn, the CSO and Founder of Deciphera Pharmaceuticals, received his Ph.D. in medicinal chemistry at the University of Kansas. Flynn said that when he established Deciphera in 2003, he could have located the company’s research labs anywhere in the country. He chose Lawrence.

Tech

CritiTech lab equipment

“I wasn’t wooed here, I came voluntarily.” Flynn said. “Even back 10 years ago there was a beginning of a desire from the thought leaders of the city wanting to bring Lawrence forward as a regional biotech hub. I wanted to be a part of that.”

Deciphera’s labs were originally located at KU’s Life Science Research Laboratories, at 1501 Wakarusa. In 2011, they moved to their downtown location.

“It’s surprising that we would have a research lab above Chico’s and the Gap, but we worked with city commission to make them comfortable with being us downtown,” Flynn said. “Lawrence is a wonderful town to work in. At least a third of our hires have been KU graduates or KU-affiliated. We have had no problem tapping into the human resources that have been available here.”

Deciphera specializes in developing cancer-fighting pharmaceuticals that use a technology called kinase inhibitors. Kinases are enzymes that transmit signals within cells to help the cells function. Kinase have “switch” mechanisms that allow the enzymes to “turn on” to perform its function, and “turn off” when not needed. Mutations in a kinase switch can cause a kinase to remain on continually, which can cause a cell to become cancerous. Kinase inhibitors work by targeting the faulty kinase switch, which cuts off the ability of tumor cells to thrive and spread.

“Our approach to cancer is not the standard chemotherapy, which is designed to kill any cell whether it is cancer or not,” Flynn said. “Kinase inhibiters are targeted therapeutics – they go into a cell and target the runaway kinase. The side-effect profile is much more favorable this way.”

Flynn said that Deciphera has spent the past five to six years focusing on researching and developing its specialized kinase inhibitor technology platform to produce drug candidates. It now has five drug candidates at various stages development that utilize the company’s technology. The ultimate goal is to advance these candidates into human clinical trials so that they may ultimately be available on the market to treat cancer patients. Clinical trials measure outcomes and assess the safety and effectiveness of a new drug or combination of drugs. New pharmaceuticals undergo three phases of clinical trials before being approved for marketing. Deciphera currently has three drug candidates in Phase I clinical trials, including one that is being developed in partnership with pharmaceutical giant Eli Lily.

Tech

Dechipera, front row left to right: Cynthia Leary, Anjanette Wilhelm & Daniel Flynn. Back row: Mike Kauffman, Bryan Smith, Linda Martin, Susan McElwain & John Lord

Flynn said that partnering with Eli Lily in the early stages of clinical trials was in Deciphera’s best interest for this particular drug. However, the company plans to conduct Phase I trials for its other drug platforms in its Lawrence labs when possible. It will then seek strategic partnerships with pharmaceutical companies once the drugs have advanced to later phases.

“Our design is to finish Phase I clinical trials in-house,” Flynn said. “It is all about risk and reward. If we have internal phase-one data that looks good, that leads to more favorable partnerships in the future.”

Deciphera recently hired Mike Taylor, a veteran of the bioscience deal-making industry, to serve as its new president and CEO. Taylor communes between Lawrence and Boston offices.

“It’s great to have him on board,” Flynn said. “He brings a good business acumen to the company.”

Deciphera currently has 16 total employees between the Lawrence and Boston offices. Although the company is currently focusing its attention on a few of its drug platforms, Flynn said that Deciphera has no shortage of other drugs with the potential to advance into clinical trials.

“We have a backlog of assets,” Flynn said. “Most companies our size have one or two assets, and they live or die based on those. We have a wealth of riches in our war chest.”

Where Deciphera uses its technology to create new drug formulations to fight cancer, CritiTech specializes in reformulating and improving pharmaceuticals that are already on the market. CritiTech is currently working on a reformulated version of the widely administered chemotherapy drug, Paclitaxel. The reformulated drug, which CritiTech has named Nanotax, performed favorably in a recent Phase I clinical trial focusing on ovarian cancer patients at the KU Medical Center.

CritiTech reformulates existing drugs using proprietary technology that transforms existing drug formulations into very fine particles. The core base of CritiTech’s technology was developed at KU by researcher, Bala Subramaniam, and CritiTech has continued to evolve and expand this technology, according to CritiTech President Matthew McClorey. Reformulating existing drugs into smaller particles can have a number of benefits, including making drugs less toxic, more effective and easier to administer.

Tech

President of CritiTech Matthew McClorey

McClorey said that CritiTech’s reformulation of Paclitaxel into Nanotax is an ideal example of what can be done with CritiTech’s technology. Paclitaxel is currently administered to ovarian cancer patients intravenously using a toxic delivery agent called Cremaphor. By reformulating Paclitaxel into smaller particles using its technology, CritiTech’s reformulated version, Nanotax, can be administered straight into the abdomen using water or saline.

“This is important because the Cremaphor creates significant toxicity for the patients. And because the Paclitaxel is administered into the vein, those toxic effects are systemic,” McClorey said. “The results of Nanotax Phase I trial indicated that it can be delivered at the site of the tumor, in a higher concentration, for a longer period of time, and without the typical side effects and toxicity that is associated with the drug that is currently on the market.”

McClorey said that CritiTech plans to move Nanotax forward in advanced clinical trials, and hopes the drug will be on the market in a few years. He also said that there is a good possibility that Nanotax will be applicable to other cancers including breast, liver and colorectal.

“We think we can improve the lives of ovarian cancer patients with this drug,” McClorey said. “We need to do expanded trials to prove that out, but that is why we are doing what we are doing – to improve the quality of life for these women and hopefully help them to live longer.”

With a solid example of what CritiTech’s technology can do well under way, the company is now starting to offer the technology’s service to other drug companies. Just as CritiTech developed a new and improved version of Paclitaxel, it wants to help other pharmaceutical companies.

“We have started providing this third-party drug development in this past year,” McClorey said. “We have had some contracts coming in from companies that are exploring the use of our technology as applied to the compounds that they are developing. Just like we developed a new and improved version of Paclitaxel, we want to help other pharmaceutical companies develop a new and improved version of their products.”

Share.

Related Posts

92 Comments

  4. Real Estate Market on

    I am not sure where you are getting your info, but good topic. I needs to spend some time learning much more or understanding more. Thanks for great info I was looking for this information for my mission.

  7. Real estate for sale in Malta on

    I used to be recommended this web site via my cousin. I’m now not certain whether or not this submit is written by him as no one else recognise such unique approximately my difficulty. You’re incredible! Thanks!

  24. prabowo presiden anjing on

    One thing I’d prefer to say is that often before buying more laptop or computer memory, take a look at the machine in to which it would be installed. In case the machine can be running Windows XP, for instance, the particular memory limit is 3.25GB. The installation of above this would basically constitute a new waste. Make certain that one’s mother board can handle the actual upgrade amount, as well. Interesting blog post.

  25. prabowo presiden anjing on

    It’s appropriate time to make a few plans for the future and it’s time to be happy. I have learn this submit and if I could I wish to recommend you some attention-grabbing issues or tips. Perhaps you can write subsequent articles relating to this article. I desire to read more issues approximately it!

  33. thuốc kích thích on

    sex nhật hiếp dâm trẻ em ấu dâm buôn bán vũ khí ma túy bán súng sextoy chơi đĩ sex bạo lực sex học đường tội phạm tình dục chơi les đĩ đực người mẫu bán dâm

  34. Property Market Malta on

    There are some fascinating closing dates on this article however I don?t know if I see all of them middle to heart. There’s some validity however I will take hold opinion until I look into it further. Good article , thanks and we want more! Added to FeedBurner as properly

  35. sex ông già on

    sex nhật hiếp dâm trẻ em ấu dâm buôn bán vũ khí ma túy bán súng sextoy chơi đĩ sex bạo lực sex học đường tội phạm tình dục chơi les đĩ đực người mẫu bán dâm

  38. Real Estate Market on

    It’s a pity you don’t have a donate button! I’d without a doubt donate to this superb blog! I guess for now i’ll settle for book-marking and adding your RSS feed to my Google account. I look forward to new updates and will talk about this site with my Facebook group. Chat soon!

  39. jual narkoba online on

    Greetings! I know this is kinda off topic nevertheless I’d figured I’d ask. Would you be interested in trading links or maybe guest authoring a blog post or vice-versa? My blog goes over a lot of the same topics as yours and I believe we could greatly benefit from each other. If you happen to be interested feel free to send me an e-mail. I look forward to hearing from you! Wonderful blog by the way!

  64. Kattintson ide on

    May I simply say what a comfort to discover somebody that really knows what they are talking about on the web. You definitely understand how to bring a problem to light and make it important. A lot more people need to read this and understand this side of your story. I can’t believe you’re not more popular because you certainly have the gift.

  67. 毛沢東殺した人数 on

    Some manufacturers package deal their serums in amber glass bottles to assist protect the ingredients from gentle — which additionally decreases the time it takes sure substances to interrupt down — but as soon as the bottle is opened and exposed to air, the substances can nonetheless change into unstable.

  69. More Info on

    Good blog! I truly love how it is easy on my eyes and the data are well written. I’m wondering how I might be notified when a new post has been made. I have subscribed to your RSS which must do the trick! Have a nice day!

  71. Lépjen az oldalra on

    The very next time I read a blog, I hope that it does not disappoint me as much as this one. I mean, I know it was my choice to read, but I truly thought you’d have something useful to talk about. All I hear is a bunch of moaning about something you could fix if you weren’t too busy looking for attention.

  72. see this here on

    I am so happy to read this. This is the kind of manual that needs to be given and not the random misinformation that’s at the other blogs. Appreciate your sharing this greatest doc.

  73. try this out on

    Do you mind if I quote a couple of your articles as long as I provide credit and sources back to your webpage? My website is in the exact same area of interest as yours and my users would genuinely benefit from some of the information you provide here. Please let me know if this alright with you. Regards!

  78. esta for america on

    Just want to say your article is as astonishing. The clearness on your post is simply spectacular and that i could suppose you’re an expert in this subject. Well with your permission let me to seize your feed to keep up to date with approaching post. Thanks 1,000,000 and please continue the enjoyable work.

  79. Deze link on

    Your style is unique in comparison to other people I have read stuff from. I appreciate you for posting when you have the opportunity, Guess I will just book mark this page.

  81. ấu dâm on

    sex nhật hiếp dâm trẻ em ấu dâm buôn bán vũ khí ma túy bán súng sextoy chơi đĩ sex bạo lực sex học đường tội phạm tình dục chơi les đĩ đực người mẫu bán dâm

  82. Volg deze link on

    Nice post. I learn something totally new and challenging on websites I stumbleupon on a daily basis. It’s always helpful to read through articles from other writers and practice something from other sites.

  84. have a peek at this web-site on

    It’s a pity you don’t have a donate button! I’d definitely donate to this excellent blog! I suppose for now i’ll settle for bookmarking and adding your RSS feed to my Google account. I look forward to fresh updates and will talk about this blog with my Facebook group. Talk soon!

  86. Lees verder on

    When I initially left a comment I appear to have clicked the -Notify me when new comments are added- checkbox and from now on whenever a comment is added I get four emails with the same comment. Is there an easy method you are able to remove me from that service? Cheers.

  87. Ver la página on

    Hi, I do believe this is an excellent web site. I stumbledupon it 😉 I am going to come back yet again since I bookmarked it. Money and freedom is the best way to change, may you be rich and continue to help others.

  88. Visite el sitio on

    I absolutely love your blog.. Great colors & theme. Did you make this site yourself? Please reply back as I’m trying to create my own blog and would love to find out where you got this from or exactly what the theme is called. Many thanks!

  92. ấu dâm on

    sex nhật hiếp dâm trẻ em ấu dâm buôn bán vũ khí ma túy bán súng sextoy chơi đĩ sex bạo lực sex học đường tội phạm tình dục chơi les đĩ đực người mẫu bán dâm

Leave A Reply

Contact to Listing Owner

Captcha Code